A man is vaccinated with AstraZeneca in Jakarta, Indonesia, June 15. Photo: AP The results showed that only 166 cases required hospitalization. Those who received two doses of the AstraZeneca vaccine were 92% effective without requiring hospitalization, while those who received the Pfizer vaccine, the figure was 94% after dose 1 and 96% after dose 2. “These findings suggest that the level of protection of people with Delta variant from hospitalization is very high. Understanding this is important in assessing the danger that Delta variant poses to the general population.” , the study authors concluded. “The effect of not requiring hospitalization because the Delta variant after one injection of AstraZeneca is 71% and after two injections is 92%. This metric really reassures India. To choose the direction, I think we should should use modeling approaches to devise different implementation strategies and compare the impact of vaccines at each stage of the epidemic,” commented Professor of Microbiology Gagandeep Kang of India. The Delta variant first appeared in India and has been classified as a “variant of concern” by the US Centers for Disease Control and Prevention (CDC), while the World Health Organization (WHO) has called it a “variant of concern”. it is a ‘disturbing variation’. The Delta variant is expected to become a common strain in the US next fall, increasing the risk of a new wave of disease in unvaccinated people later this year.

A healthcare worker is vaccinated against COVID-19 at a hospital in Kolkata, India. Photo: AP In India, the number of infections on May 30 was 165,553 cases, the lowest level in the past 6 weeks. The number of deaths also tended to decrease, to 3,460 cases and the third day in a row below 4,000 cases.

The vaccination campaign is being accelerated by India, although vaccine supply remains a big challenge. As of May 30, India has injected more than 212 million doses of the vaccine, ranking third in the world after China and the US. About 12% of the population was vaccinated with at least one dose, of which 3.1% were fully vaccinated. Prime Minister Narenda Modi’s government said on May 30 that about 120 million doses of the vaccine will be included in the vaccination program in June, a significant increase from 79.8 million doses in May. , government advisers also said that India could reach a supply of 2 billion doses of vaccine between August and December this year, mainly from two domestic manufacturers, the Serum Institute of India (Serum Institute of India). SII) – responsible for producing vaccine samples of AstraZeneca and Bharat Biotech Company, the focal point of domestic production of Covaxin vaccine. In June, the government will provide 60.9 million doses of vaccine to the states to vaccinate health workers along with some other forces on the frontline against the epidemic, people over 45 years old. About 58.6 million doses will be ordered and distributed by state governments and private hospitals. Malaysia on May 30 recorded 6,999 new cases of COVID-19 and was the 5th consecutive day of outbreaks of infection. The government of this country plans to set up more large-scale vaccination centers, mobilize private medical staff to participate in vaccination campaigns in the context of Malaysia preparing to implement a nationwide shutdown. for a period of two weeks, from June 1-14. Medical staff take samples for COVID-19 testing for people in Selangor, Malaysia on May 23, 2021. Photo: THX/VNA Speaking at an online press conference on May 30, Malaysian Minister of Science, Technology and Innovation Khairy Jamaluddin said the government will establish five new large-scale vaccination centers in Kuala Lumpur and have Two more similar centers could be established in the northern state of Penang and the southern state of Johor. Each of such centers has the capacity to administer 40,000 doses of vaccination per day. The Government will also conduct training and training for doctors and nurses to perform vaccinations, stemming from the fact that some vaccines need different handling and storage methods and are different from conventional vaccines. Mr. Jamaluddin also said that the supply of vaccines will increase in the near future, so the government will mobilize manpower from hospitals and private medical centers to voluntarily participate in the vaccination campaign. According to Jamaluddin, Prime Minister Muhyiddin Yassin’s government is also expected to set up mobile vaccination centers at roads to vaccinate people. Currently, about 6% of Malaysia’s 32 million people have received at least one vaccination. In the Philippines, the head of the Philippine Government’s COVID-19 Task Force, Mr. Czar Carlito Galvez Jr, said on May 30 that more than 5 million doses of the vaccine have been administered to people, after nearly 3 months of implementation. vaccination campaign. People wear masks to prevent COVID-19 infection in Manila, Philippines. Photo: THX/VNA Most of these were administered to priority groups, including 1.4 million doses for healthcare workers, 1.368 million doses for the elderly and 1,150 million doses for people with underlying medical conditions. Vaccines introduced in the Philippines include Sinovac, AstraZeneca, Sputnik V and Pfizer. Galvez also said that in June, the Philippines is expected to receive an additional 10 million doses of vaccine, including the amount of vaccine through the Covax Initiative program, 2.3 million doses of Pfizer vaccine, 2 million doses of AstraZeneca vaccine and 1 million doses of vaccine. Sinovac vaccine. The first batch of 250,000 doses of Moderna is also expected to arrive on June 21. The administration of President Rodrigo Duterte has set a target of vaccinating about 70 million people or more than 50% of the population this year. However, this plan is facing major challenges. In addition to the limited supply of vaccines, the lack of confidence in Chinese vaccines is also a big barrier. It was Mr. Duterte who recently had to speak to reassure, urging people to avoid the mentality of choosing a vaccine, but to see that having a vaccine to inject is already a good thing.

Tokyo’s overlapping messages have drawn criticism, as the country lags behind countries like the US in vaccinations. Japan has recorded about 695,000 new coronavirus infections and 12,000 deaths. The country is facing a new wave of infections in the context of the Tokyo Olympics approaching. Many Japanese prefectures are still in a state of emergency to limit the spread. Tokyo has contracts with three suppliers, under which it will have 120 million doses of AstraZeneca, 50 million doses of Moderna (to be completed by the end of September) and is negotiating an additional 50 million doses, along with 194 doses of Pfizer calculated. until the end of this year. With this number, Japan will have enough vaccine to vaccinate the entire population of 126 million people, according to Japan Times . On May 21, the country approved the use of the Moderna vaccine for people 18 years of age and older, but AstraZeneca has not yet been approved for the public. The Japanese government’s vaccination program is using the Pfizer vaccine, while the Moderna vaccine will be rolled out from next week in Tokyo and Osaka. Many concerns when using vaccines The biggest barrier to new vaccine doses available in Japan is the screening process, which evaluates efficacy and safety based on clinical trial data. Like other covid-19 vaccines, doses of AstraZeneca are classified as an emergency measure in pandemic response in Japan, used only when the Health Ministry allows the city governments. The licensing action requires a separate approval process, which includes a subcommittee on vaccines from the Ministry of Health meeting to discuss the use of the AstraZeneca vaccine in Japan in a broader context based on: fruit; alternatives from Pfizer and Moderna; Japanese immunization schedule and potential side effects. Pfizer’s covid-19 vaccine is shipped in Tokyo, Japan, February 16. Photo: AP. However, the road to deploying vaccines in the real world is still fraught with thorns, due to growing concerns about potential side effects of vaccines. There have been reports of a small number of people receiving the AstraZeneca vaccine developing blood clots, including in some cases death. This condition usually occurs in younger age groups. The UK reported 79 cases of AstraZeneca vaccination at the end of March, out of 20.2 million doses administered. As a result, 19 people died, of which 11 were under the age of 50. This has led some countries to restrict vaccination of the elderly – a direction that seems unlikely for Japan. The plan is still open Japan has given the Pfizer vaccine to the elderly and will start providing the Moderna vaccine at mass vaccination sites on May 24. The country has guaranteed enough doses for more than 122 million people, of which more than 110 million people aged 16 and over are allowed to receive the vaccine. Vaccination site for people 65 and older in Otsu, Shiga Prefecture, Japan on April 12. Photo: Kyodo. Given that Japan already has sufficient supplies for the vaccination campaign for the elderly, with a goal of completing it by the end of July, the use of the AstraZeneca vaccine for this age group in Japan is unlikely. On May 21, the vaccine subcommittee continued to discuss what should be done with the AstraZeneca vaccine. It is not yet clear when a decision will be made on the matter, the Health Ministry said. With so many people waiting to be vaccinated, one expert argues that the government should not ignore any vaccine. Otherwise, the Japanese public, with the exception of the elderly, will not receive any vaccines until the fall. “We may not even get there by the end of the year,” Gakushuin University economics professor Wataru Suzuki wrote in a commentary for Nikkei . “Certainly people who want to be protected from the virus as soon as possible have a need to be vaccinated, similar to those who want a vaccine passport to be able to travel abroad on business, and the Ministry of Health is going too far by how to eliminate options,” he argued. Where will 120 million doses go? The Japanese government has reached an agreement to purchase 120 million doses of the AstraZeneca vaccine, all manufactured in Japan, using undiluted solutions from the United States. Of these, 30 million will be manufactured by Daiichi Sankyo and KM Biologics, and 90 million doses will be manufactured by JCR Pharmaceuticals. However, it is not clear how many of these vaccines have been produced Nikkei Asia. Imports and production begin this spring. Daiichi Sankyo and KM are both preparing to ship the vaccine once it is approved by the government. The mid-range drug maker has started production using equipment and technology from AstraZeneca. JCR has announced plans to build a new factory. The US and Japan will have to find a way to handle the 120 million doses of the coronavirus vaccine developed by the Universities of Oxford and AstraZeneca without any plans to use them. Photo: Reuters. AstraZeneca says its completed vaccine can be stored in the refrigerator for at least half a year at 2-8 degrees Celsius. It’s uncertain at this point how many vaccines are ready to be manufactured. If there is no decision on where to use the vaccine in the next six months, the stockpile could expire. The US has yet to start rolling out the AstraZeneca vaccine. However, the country has agreed to purchase 300 million doses and already has shipments ready to deliver. Currently, the US plans to ship the unused vaccine elsewhere.

Previously, on February 24, more than 117,000 doses of Covid-19 vaccine were first produced by the British AstraZeneca Company, and imported by the Vietnam Vaccine Joint Stock Company (VNVC) under the permission of the Ministry of Health. present in Vietnam. Next, on April 1, 811,200, the first Covid-19 vaccine dose of the Covax Facility program through UNICEF arrived in Vietnam. By the end of May 12, the whole country had 62 provinces and cities completed the vaccination of Covid-19 with 942,030 injections of Covid-19 vaccine of AstraZeneca for people who are health workers. are directly treating Covid-19 patients, medical staff perform tasks such as sampling, testing, tracing, members of Covid-19 community groups, steering committee for epidemic prevention all levels, police forces, the army according to the Resolution 21 / NQ-CP of the Government dated February 26, 2021. Step 1: Access to https://www.bluezone.gov.vn or directly download at App Store or Play Store. Step 2: Once downloaded, the app will ask for Bluetooth permission to record contact with other Bluezone installed users. If Bluetooth isn’t open, drag the status notification bar and turn on Bluetooth; Or go to Settings, select Bluetooth and turn it on. Step 3: After the installation is complete, click Scan Around. If someone near you less than 2m has used Bluezone, the application will automatically identify these users and put them on the contact list.

According to the news agency DW The final decision on whether or not to give up the copyright for the COVID-19 vaccine will be decided by the 164-member World Trade Organization (WTO). Of these, more than 100 countries have supported negotiations towards the abolition of measures to protect intellectual property rights with the COVID-19 vaccine. However, as long as a country disagrees, the WTO cannot approve this proposal. However, there are still countries that oppose the US move. Press conference on this issue on May 6, a spokesman for the German government warned that this would make pharmaceutical companies and biotech companies lose motivation to research and develop vaccines, negatively impacting. the entire vaccine industry in general. Therefore “the protection of intellectual property is a resource for creativity and must be maintained in the future”. The waiver of the vaccine license does not help much in the goal of increasing world vaccination coverage. The reason, “the factors that limit the number of vaccines vaccinated are production capacity and quality standards, not the copyright story”. Protect effort and gi Oh degree ng l Ugh c research According to radio CNN In the current context, giving up intellectual property rights with vaccines is a very complicated problem. A vaccine that has been successfully researched and developed is a collection of a series of different ingredients and materials and each ingredient and ingredient is copyrighted by at least one company or researcher. wisdom. For example, inside the vaccine company Pfizer (USA) and Biotechnology Company BioNTech (Germany) produces 280 ingredients and materials are licensed from many parties from 19 countries. Once a waiver scenario occurs, anyone can freely access and use the ingredients and ingredients in this vaccine – causing significant damage to Pfizer, BioNTech and others. holding the copyrights of those ingredients and materials. Medical staff in the capital Berlin (Germany) prepare the vials of vaccines to be vaccinated in April. Photo: DW “A single dose of vaccine contains all intellectual property from licensing agreements, copyrights, industrial designs to trade secret protection laws, patent secrets. If the copyright for the COVID-19 vaccine is abandoned, how can this be enforced? ” – Intellectual property rights expert Achal Prabhala of the Shuttleworth Foundation (South Africa) analyzed. Mr. Prabhala also affirmed that intellectual copyright is the backbone of the entire pharmaceutical and medical industry because it is difficult and time-consuming to research and create a product that is safe to use in humans. The recognition and protection of copyright is a way of respecting the efforts of researchers. The risk of technology secrets disclosure Another equally important issue when it comes to vaccine licensing issues is the protection of vaccine technology and formulation. Currently, Pfizer, BioNTech and Moderna (USA) are the pharmaceutical companies and technology companies leading the use of new generation mRNA technology to significantly increase the effectiveness of vaccines. This technology is also evaluated to be highly applicable not only in the prevention of COVID-19 but also in other diseases in the future. Meanwhile, pharmaceutical companies in Russia or China have not fully applied this technology; Vaccines that these countries produce and put into use do not have mRNA technology, so the effectiveness level is also somewhat not as high. “Pfizer and Moderna took years of research to develop these vaccines. China and Russia and other countries both want to access it. Their goal is to possess the underlying technology to make vaccines not only to prevent COVID-19 but also for other diseases, ”said former US Ambassador to China Gary Locke. Reuters . In the event that the vaccine rights are abandoned, Beijing will likely force the above-mentioned pharmaceutical firms to hand over the technology if they want to operate in the Chinese market. On the other hand, Beijing may also ask other companies to generate income for such information without fear of being criticized for stealing foreign company secrets. If pharmaceutical companies refuse to provide information, they will face many legal consequences. Remember, intellectual property rights have been a big question between the US and China for many years now, and has been one of the main reasons for the outbreak of the US-China trade war in 2018. • EU completed a contract to buy 1.8 billion vaccine money Associated Reuters May 10 quoted Mr. Thierry Breton – Commissioner in charge of industry and domestic markets the European Union (EU) said that this bloc will not continue to buy vaccine COVID-19 by the pharmaceutical company AstraZeneca (UK-Switzerland). Swedish) production. The reason AstraZeneca has not met its commitment to supply vaccines to the EU. By the end of the first quarter of 2021, the EU received only 67 million doses of vaccine from AstraZeneca, although the initial target was 300 million doses. It is expected that in the second quarter, the EU will receive an additional 250 million doses. The remaining 280 million doses will be delivered to the EU by AstraZeneca during the last six months of 2021. In addition to legal disputes with the EU, AstraZeneca’s vaccine reputation has also deteriorated due to information related to adverse reactions. Some European countries such as Denmark have stopped using AstraZeneca’s vaccine, while in most other countries in the region, this vaccine is only used for people over 55 years old. After discontinuing the contract with AstraZeneca, the EU plans to order more vaccines using mRNA technology such as Pfizer / BioNTech or Moderna. In fact, European Commission President Ursula von der Leyen said over the weekend that the EU has officially completed a contract to buy up to 1.8 billion doses of Pfizer / BioNTech vaccine over the next two years.

The image was taken inside a vaccination center located in the railway museum of Catalonia in Vilanova i La Geltru City, Spain. Persons receiving AstraZeneca’s Covid-19 vaccine rest at the follow-up area after vaccination. (Image: Getty Images) Medical staff giving flu vaccines to residents not participating in the community Covid-19 vaccination program established at the National Museum of Science and Technology of Leonardo Da Vinci in cooperation with the Leonardo Da Vinci Hospital in Milan, Italy. (Photo: EPA) Chairs in the post-vaccination monitoring room in the city of Naples, Italy, are placed at a guaranteed social distance. (Image: Getty Images) “Medical train” Akademik Fyodor Uglov in Kuytun village, Irkutsk region, Russia. The train is being used as a mobile diagnostic center, and staff on board are deploying Sputnik V vaccination to locals along the East Siberian Railway. (Photo: TASS) A Covid-19 vaccination clinic on the square of the SNCF station vaccination center in Nice City, France. (Photo: Shutterstock) The Robert Poirier Athletics Stadium in Rennes, Britany Province, France, has been transformed into the Pfizer / BioNTech Covid-19 vaccination center. (Image: Getty Images) Medical staff preparing to vaccinate at the Metropolitano Stadium in Madrid, Spain. (Photo: AP) Poland’s Wroclaw city prepares for a mass vaccination campaign at the city stadium. (Photo: Shutterstock) Aalborg Symphony Orchestra performs at an immunization center in Jutland, Denmark. (Photo: EPA) Residents sit in cars waiting for Covid-19 vaccinations at an immunization site at NRG Park complex, Houston City, Texas, USA. (Photo: AP) Cars move through traffic posts leading to the vaccination center inside Dodgers Stadium in Los Angeles, California, USA. To date, the state of nearly 40 million people has had nearly 19 million doses of Covid-19 vaccine, with nearly 6.9 million fully vaccinated. (Photo: AP) The line of vehicles waiting for the Covid-19 test at Dodger Stadium, Los Angeles City. The United States, the country most heavily affected by Covid-19, stressed that vaccination was the way to bring the country out of the pandemic. (Photo: AP) Photographed while waiting in line for AstraZeneca’s Covid-19 vaccination at the Olympic Stadium in Montreal, Canada. (Photo: AP)

Developed by a small group of the most talented vaccine scientists on the planet and industrially produced by the leading pharmaceutical giant with many prestigious certifications, Vaxzevria (the official new name for the Oxford / AstraZeneca vaccine in Europe) has been making hot headlines for many months. But not the kind that manufacturers have high expectations for. Months later, the manufacturer was not only caught in the political conflict between the EU and the UK, but also by the increasingly complicated conflicts. As a result, many governments around the world have recovered parts of Vaxzevria (some countries call it Covishield). Even when the third wave of outbreaks broke out in Germany and the EU, followed by a number of people claiming they wanted to be injected with any vaccine except for AstraZeneca. What’s wrong with that? The following survey by reporters Der Spiegel has reorganized the stories surrounding AstraZeneca in recent weeks to envision the disaster facing not only the pharmaceutical company but also many other countries. British Prime Minister Boris Johnson (center) in an AstraZeneca vaccine factory. The Story of AstraZeneca The story of Vaxzevria begins at the Faculty of Medicine Nuffield, a research center on the eastern edge of the University of Oxford city. On January 30, 2020, a group of prominent researchers gathered there, just one day before the Brexit event and one day before the first two COVID-19 infections were announced in the UK, to be exact. is in York, 300 km away. For weeks, researchers continuously watched news about an outbreak of a virus in Wuhan (China), in a restless mood. As Prime Minister Boris Johnson’s governmental capacities are fully focused on leaving the EU, scientists at Oxford discuss how they can do to save the world. Among those present that day was Sarah Gilbert (a mediocre professor at the Jenner Institute) who was experimenting with yeast in a brewing research laboratory before becoming a world-renowned vaccine expert. Ms. Gilbert has researched on vaccines against malaria, Ebola and MERS, and is also preparing vaccines for “Disease X” – the next major pandemic that scientists are working on. . Ms. Gilbert (who has been studying the SARS-CoV-2 genetic code for weeks) has surprised colleagues by asserting that a vaccine will soon be available. At the time, Ms. Gilbert was working on phase 2 of Phase 1 clinical trials of a vaccine against MERS (Middle East Respiratory Syndrome) caused by a virus in the coronavirus family. By March 2020, Oxford experts have completed the first batch of new vaccines used to destroy SARS-CoV-2. The swine clinical trials in Surrey County have shown promising results. But obviously a huge amount of vaccine is needed, as much as possible. So Oxford started looking for partners in the pharmaceutical industry, and the first choice was pharmaceutical giant Merck (USA). But because Mr. Donald Trump’s “America First” thought made the British hesitant when working with Americans and the deal with Merck broke down. Speaking later on LBC radio, UK Health Minister Matt Hancock posted on the forum explaining that he did not want to enter into a contract that would allow the first batch of Oxford vaccine to be given to other countries. In April 2020, AstraZeneca’s Anglo-Swedish joint idea was born. Mr. Pascal Soriot, CEO of AstraZeneca. Pascal Soriot and AstraZeneca When Pascal Soriot took over AstraZeneca in 2012, the company was at a bottom: stock prices plummeted, and the risk of losing its drug patents. Soriot is deep into AstraZeneca: instead of reducing costs, he invested in product development, bought more companies, and resisted Pfizer’s American acquisitions. Today, AstraZeneca is the 2nd largest company in the UK. At the age of 61, Mr. Soriot soon learned to build himself. Raised up in the Paris suburbs and his father passed away when his son Soriot turned 20 years old. Soriot then enrolled in the Paris Business School (HEC) and entered the pharmaceutical industry. In 2020, AstraZeneca’s CEO Soriot announced that his company was planning to tackle a very difficult public health problem: producing vaccines against COVID-19. AstraZeneca initially announced a partnership with Sarah Gilbert and other Oxford scientists. AstraZeneca plans to export vaccines globally at prices ranging from $ 2 to $ 5, and aims that poor countries will have access to vaccines as quickly and equally as possible. At the same time, Soriot also assured Prime Minister Boris Johnson that would provide the first and exclusive large quantity of vaccine to the UK. However, the AstraZeneca staff said that Soriot was subjective in not considering the possible consequences of failure. Without hesitation, Soriot approaches the vaccine strategy as it does with all of its projects. AstraZeneca is committed to producing 300 million doses of the vaccine for the EU by mid-2021, as well as another 100 million doses for the UK. AstraZeneca is producing Vaxzevria in at least four plants in Europe; Two of them are Oxford Biomedica and Cobra Biologics (both located in the UK); The other two facilities are Thermo Fisher and Halix (located in Belgium and the Netherlands). The four factories are operated by subcontractors, not by AstraZeneca. And at least two of them have had problems right from the start. At first, Thermo Fisher produced fewer vaccines than expected. And Cobra Biologics does not work synchronously. The Dutch health expert, Wilbert Bannenberg, was not surprised by AstraZeneca’s vaccine production glitch when it came to the hundreds of ingredients used in vaccines like Vaxzevria, even with small deviations in the ingredients. The raw material also causes the finished product to be discarded. By the end of 2020, it was clear that AstraZeneca was having difficulty in the contracts it had to make. Soriot is wondering whether to leave the UK or leave the EU. And the owner of Downing Street began to form a specialized vaccine force consisting of famous experts and scientists. Led by biochemist and venture capitalist Kate Bingham, the force not only created multipurpose vaccines for the British, but also built the UK vaccine industry. In other words, the UK offered vaccine developers an offer they could hardly turn down. Gambling customers’ trust Vaxzevria is the third vaccine to be approved in Europe, after BioNTech / Pfizer and Moderna. But by the fall of 2020 it appears that AstraZeneca’s pandemic studies have become inaccurate. For example, about 3,000 test subjects received half an injection for their first phase, and a full dose for the second injection. Both Oxford and AstraZeneca disagreed in the notion that half the dose was an attempt to act. good idea. AstraZeneca has been criticized because it basically ended up calculating the mean of the data for different groups of test subjects. An even bigger problem is the lack of seniors to include in the study. The Standing Committee on Immunization (STIKO) of the Robert Koch Institute (Germany’s center for disease control) initially recommended AstraZeneca only test 18 to 64 years old, and invisibly turned the island. Inoculation in Germany is wrong. With a feeling of discomfort from a congestion in the vaccine supply, and not yet on any scientific basis, but French President Emmanuel Macron has declared the AstraZeneca vaccine “does not budge at all for people over 65” . Since that time, the vaccine has been ranked 2 in every European country except the UK. In the US, the AstraZeneca vaccine has not even been approved even though President Trump ordered 300 million doses required by the end of May 2020. At first it seemed that AstraZeneca was not completely transparent with Americans when covering the truth about A test subject fell ill at an early stage of the trial. But that is not the last malfunction. In March 2021, AstraZeneca announced that its vaccine was 79% effective in preventing symptomatic infections. But US officials believe that the pharmaceutical company’s data is out of date and may falsify the results. In March 2021, news began to circulate threatening to destroy confidence in AstraZeneca. In some countries, people vaccinated with the Vaxzevria vaccine have developed an embolism caused by a blood clot in the brain, also known as sinus venous thrombosis (CSVT). On 29 March 2021, the Paul Ehrlich Institute (German institution of health management) recorded 31 cases of CSV out of 2.7 million vaccinated people in Germany. Most affected young women. 9 people died. Fearful, some countries have now ended contact with AstraZeneca. Until recently, the European Medicines Agency (EUMA) admitted for the first time that there is a link between thrombosis and Vaxzevria, but EUMA still recommends the Vaxzevria vaccine for all age groups. According to a survey, 23% of French people consider Vaxzevria safe, in Germany it is 32%. Norway and Denmark stopped using the vaccine Vaxzevria. Thrombosis and death were also seen in Britain for the first time. Oxford University has suspended a vaccine trial in children. Experts are on the verge of despair. Ms. Nina Gatter (a vaccinator from North Rhine-Westphalia, Germany) criticized AstraZeneca when saying that the company did not properly display concerns from the skeptical psychology of public opinion. In Europe, there has been growing skepticism and has delayed the vaccination campaign. Many were vaccinated later than planned, while others used different vaccines. Consequences affect the chain elsewhere. The Covax initiative is currently heavily dependent on the AstraZeneca vaccine. The consequences of this lack of trust can be seen in South Africa. The government stopped vaccinating people after it discovered a mutation. The slow results of the COVID-19 vaccinations in South Africa, meaning substances created with the hope of saving the world, are now piled up in stock.

The world has exceeded 147 million Covid-19 patients, of which more than 3.11 million people died. The report also found that more than a billion doses of the vaccine have been injected globally. Sheet New York Times “Even though one billion doses of vaccine have been injected, Covid-19 has spread to almost every country in the world”. Because the number of one billion doses is not enough compared to estimated nearly 8 billion people in the world. According to the data of Our World in Data (Oxford University, UK), 82% of the dose of vaccine administered is in high-income and middle-income countries. Only 0.2% of the dose is allocated to low-income countries. “Fire pan” Covid-19 in India Data of New York Times This shows that India is the country with the number of Covid-19 cases accounting for only one third of the world. On average, this country has an additional 260,000 people infected with nCoV every day. The unusual increase in India is attributed to the double mutation. More than 2,000 people die from Covid-19 every day, bringing the total number of fatal illnesses to over 200,000. Experts say these numbers could in fact be more and more terrible. The luxury thing for India right now is oxygen, oxygen tanks. Thousands of patients died on the way to the hospital or lack of oxygen to breathe, the medical facilities were overwhelmed, the crematorium was burning everywhere. The Indian Serum Institute is the largest producer of vaccines in the world, but the proportion of people in the country vaccinated against Covid-19 is surprisingly low. Approximately 8.6% of the population received at least one dose of Covid-19 vaccine. Health experts are concerned that transforming the COV strain in India could create a “domino storm” for other countries around the globe. The double mutation was more contagious, while the vigilance in many places began to let the guard down. Another hot spot in Asia is the Philippines. After Indonesia, the Philippines became the second country in Southeast Asia to have the number of Covid-19 cases exceeding the one million mark. According to the AP The Philippines’ Ministry of Health recorded 8,929 new cases on April 26, bringing the country’s total number of cases to 1,006,428, including 16,853 deaths. Philippine health officials are looking at the possibility of prolonging the blockade in the Manila metropolitan area. A Covid-19 patient awaits admission to hospital in South Delhi, India. Photo: Atul Loke / The New York Times. Many new strains appeared Data from New York Times shows that more than 50% of Israel’s population has been vaccinated with 2 doses of Covid-19 vaccine. It is the country with the fastest immunization rates and speeds in the world. Israel is also expected to be the first country globally to achieve public immunity. In the UK, where the virus strain B.1.1.7 was found, nearly two-thirds of people 18 years of age and older were vaccinated against at least one dose of Covid-19 vaccine. Compared to its population size, the UK is the country with the lowest proportion of people with Covid-19 in Europe. In the US, the country’s officials have just confirmed that they will aid India with the Covid-19 vaccine, after the tragedy that this place is suffering. According to the Guardian, The US will share 60 million doses of AstraZeneca’s vaccine because it has enough demand for the people. Professor Barry Bloom, former rector of the Harvard TH Chan School of Public Health, said: “India has been caught off guard when the number of Covid-19 cases has decreased and they subjectively believe that the epidemic is over. The US and other countries should learn from this when deciding on all policies during a pandemic. Dr. Robert Murphy, Executive Director of the Institute of Global Health, Northwestern University, believes that the United States has a great responsibility for sending unused vaccines to other countries. “We have to think globally and how we can help other countries. If not, we will never be able to put out the whole fire. ” The number of new US nCoV infections every day in the US is falling sharply, but still at an alarming rate. Experts found this trend to be similar to last year when the US seemed to have suppressed the translation, when it suddenly spiked the number of cases again. One was vaccinated by AstraZeneca at Milan Military Hospital. Photo: Alessandro Grassani / The New York Times. Last week, scientists at Texas A&M University (USA) also discovered 3 new virus strains: BV-1, BV-2, and BV-3, analyzed from samples of students and lecturers in the school. . In particular, strain BV-3 is a mixture of more than one strain of SARS-CoV-2. Experts are still not clear about their virulence, but they fear this will be the cause of the upcoming outbreaks. The proportion of new cases of SARS-CoV-2 in most South American countries is high. In Brazil, the number of new patients has begun to decline but remains at an alarming rate, especially since the country has not been able to control the processing of the highly contagious strain P.1. By the morning of April 27, Brazil had recorded more than 14.3 million people suffering from Covid-19, nearly 391,000 deaths. In Europe, the vaccination rate is slower than that of the US and Canada, the number of nCoV infections is still especially high in France, Germany, the Netherlands, and Sweden … In particular, Turkish President Recep Tayyip Erdoğan has just issued an injunction. spread across the country from the evening of April 29 to the end of May 17 in order to limit the spread of Covid-19. Turkey has recorded a sharp decrease in the number of new daily nCoV infections from 63,000 (recorded on April 16) to below 39,000 (statistic on April 25). However, the daily number of deaths from Covid-19 has remained above 300 people in the past week. In addition, on the evening of April 26, the European Union (EU) announced a lawsuit against vaccine pharmaceutical company AstraZeneca because it said that the company did not keep the vaccine supply agreement. According to the Bloomberg, AstraZeneca recently delivered 25% of the Covid-19 vaccine that the EU is expected to receive by the first quarter of 2021. At the same time, the company also plans to provide the EU with about 70 million doses in the second quarter, compared with 180 million. expected in the contract, according to the statement dated 12/3.

AstraZeneca’s COVID-19 Vaccine. Photo: VNA broadcast Due to the complexity and urgency of the situation, the provision of vaccines individually to each organization is a challenge, the institute’s announcement noted. We urge all organizations and individuals to access vaccines through public agencies and the private health care system. ”| In addition, from July next, the country can increase production of vaccine AstraZeneca to 100 million doses / month, significantly increased from the current 60-70 million doses per month. However, this production growth milestone is two months later than originally intended. The same day, Prime Minister Thailand Prayut Chan-o-cha said the country will seek to buy about 35 million additional doses of COVID-19 vaccine from two or three other manufacturers, in addition to the 65 million doses already ordered. Prime Minister Prayut Chan-o-cha said this would complement the government’s purchase of 65 million doses of vaccine from two manufacturers, AstraZeneca and Sinovac Biotech, according to a Vietnam News Agency correspondent in Bangkok. Of the 35 million doses of the new vaccine, 10-15 million will be bought by the private sector to inject their employees and this will save the government money. Thailand started its vaccination campaign on February 28 with priority given to high-risk people who are health professionals and those in close contact with patients. The country’s vaccination campaign will initially rely on imported vaccines developed by China-based company Sinovac Biotech and will then use the vaccine AstraZeneca contracted by the company Siam Bioscience to make domestically for injection. vaccinated for about 35 million people. As of April 20, more than 2.1 million doses of COVID-19 vaccine, including 117,000 doses of AstraZeneca vaccine, arrived in Thailand. To date, Thailand has received a total of 712,610 doses of the COVID-19 vaccine.

From Notker Blechner, tagesschau.de So far it has seemed that children are largely spared from Corona. Many who were infected with Covid-19 had asymptomatic or mild disease. Serious illnesses were rare. “I haven’t had a bad case so far,” says pediatrician Axel Gerschlauer from Bonn, regional spokesman for the professional association of paediatricians. But there have also been deaths in children in connection with a corona infection. Long-term effects are even more common. More than 250 cases of the PIMS syndrome (“Pediatric Inflammatory Multisystem Syndrome”) have already been counted. This is an immune reaction that occurs a few weeks after infection, especially in children, and can be life-threatening.

Some children suffer from long-term effects

Surveys from abroad are also alarming, according to which numerous children and adolescents suffer from “long covid”, i.e. post-viral symptoms weeks or months after the infection. According to recently published data from Great Britain, 15 percent of adolescents between the ages of eleven and 16 complained of persistent headaches, sudden learning disorders or a drop in performance in sports five weeks after the corona illness. In a study by a clinic in Rome, it was even found that almost half (43 percent) of the children infected with Corona had at least one symptom that was affecting them four months later. “Children are not the drivers of the pandemic,” said Jörg Dötsch, President of the German Society for Child and Adolescent Medicine. However, since February the incidence among the youngest has also increased significantly in Germany. On the one hand, this may be due to the numerous tests that were carried out in schools. On the other hand, the proportion of people over the age of 70 in cases of illness has fallen significantly, as they have largely been vaccinated. Pediatricians consider it important to vaccinate children and adolescents as quickly as possible – especially in view of the mutated South African, British and Brazilian corona viruses. This is the only way to achieve herd immunity. Experts now believe that 80 to 90 percent of the population should be vaccinated to ensure collective protection. Because the more contagious the virus, the higher the vaccination rate must be. “If vaccination is not carried out across all population groups, extensive immunity cannot arise in the general population,” says Thomas Fischbach, President of the Association of Pediatricians. Heinz Hilgers, President of the Child Protection Association, also says: “We will not get out of this pandemic without vaccinations for children.”

Schoolchildren in Israel already vaccinated

Vaccine manufacturers understand the importance of children and teenagers. “Younger children, who make up a large part of the world’s population, play a crucial role in our fight against Covid-19,” said BioNTech and Pfizer recently. The German-American company duo wants to accelerate the development of vaccines for children and adolescents. BioNTech boss Ugur Sahin spoke of promising studies at the analysts’ balance sheet conference. A phase III study in 12 to 15 year olds was particularly successful. The vaccine has been shown to be safe and effective in this age group. None of the vaccinated 2260 participants in the study was sick with Covid-19, it said. “The first results of the study in adolescents indicate that children are particularly protected by the vaccination,” said CEO Sahin. BioNTech-Pfizer plans to apply for emergency approval in the USA and the European Medicines Agency (EMA) in the coming weeks. Pfizer boss Albert Bourla is confident that the first young Americans will be vaccinated in the US before the start of the next school year. So far, the drug has been approved for people aged 16 and over in countries such as the USA and Israel. In Israel, the first pupils under the age of 18 were vaccinated.

The very little ones still have to wait

Now there should also be clinical tests for vaccines in children between six months and eleven years. If the study is positive, the vaccine could be used in the youngest from the beginning of 2022. The US company Moderna and the British-Swedish pharmaceutical company AstraZeneca were faster. They had started testing their corona vaccines on younger children even before BioNTech-Pfizer. The results of the Moderna study for the vaccine in 12 to 17 year olds are expected in the middle of the year. The US FDA has approved Moderna tests on children aged six months to twelve years. AstraZeneca began a study of its vaccine in 6 to 17 year olds in the UK in February. Johnson & Johnson is also planning its own pediatric studies. The European Medicines Agency has obliged the four major suppliers to also test their vaccines for children.

BioNTech and Pfizer clearly ahead

But so far BioNTech-Pfizer has been ahead in the race for children’s vaccines. Analysts like Daniel Wendorff from Commerzbank are convinced of this. The Mainz vaccine is so far the only one that has been proven to be effective in 12 to 15 year olds. BioNTech and Pfizer would have such great market power anyway that the two companies could quickly increase production. When it comes to absolute vaccination doses and the availability of data, BioNTech-Pfizer is a leader, says Wendorff. The EU is increasingly relying on BioNTech-Pfizer. Brussels is about to finalize a huge order for 1.8 billion cans, the majority of which are for children and young people. The rest are booster vaccinations that are likely to be required in the years to come.

First approval in late summer?

Thomas Mertens, the chairman of the Standing Vaccination Commission (Stiko), has shown confidence that in Germany Corona vaccine available for children at the end of the year will be. Association president Dötsch even hopes that “we will get a vaccine for 12 to 15 year olds in late summer or autumn at the latest, for smaller children it will probably take longer”. However, other experts warn against being too optimistic. “Children are not little adults,” says pediatrician Gerschlauer. You can’t give them half the dose just because they’re half the size of adults. The immune system of the little ones is completely different. In addition, there is the problem that it is more difficult to find children as test subjects for studies. Smarter would like to see a vaccine approved for the youngest of our society as soon as possible. Because children in particular are the biggest losers in the corona pandemic. In his practice he currently counts more young patients with mental disorders than ever before. “Many have eating and sleeping disorders or even depression.” This is confirmed by Jörg Dötsch, President of the German Society for Child and Adolescent Medicine: “70 to 90 percent of children are under severe psychological stress from the pandemic,” he estimates. “We’re really worried about the little ones.”

The Peter Doherty Institute of Infectious and Immunology will join Monash University, the University of Melbourne and a number of other research centers as the recipients of funding to develop the above plan. Vaccination against Covid-19 in Australia is facing many challenges due to lack of supply. (Source: Reuters) Scientists at the Peter Doherty Institute said they are working on a “preventive” vaccine with mRNA technology that can be modified to fight variations. Mr. Merlino said that this plan is an important event, not only for Victoria but for the entire country of Australia. Besides, he affirmed that the support budget will be increased when the project is developed in the future. Australia is currently only capable of producing AstraZeneca’s vaccines, with the initial plan being that the CSL facility in the city of Melbourne will produce more than 50 million doses. Vaccination against Covid-19 in Australia is facing many challenges due to the lack of vaccine supply, as well as the safety of the vaccine in relation to the side effects of thrombosis. (Reuters)

Acting Premier of Victoria, James Merlino. (Source: abc.net.au) On the morning of April 21, Mr. James Merlino, acting Premier of Victoria ( Australia ) announced that it would provide AUD 50 million (approximately US $ 38.6 million) to launch a project to develop vaccine production technology for mRNA at state vaccine research facilities. Under the project, it will take at least 12 months for Australia to be able to produce any vaccine under it mRNA technology . The move will pave the way for vaccines using mRNA technology such as Pfizer and Moderna to be produced in Australia, according to the Vietnam News Agency correspondent in Sydney. The Peter Doherty Institute of Infectious and Immunology will join Monash University, the University of Melbourne and a number of other research centers as the recipients of the funding to develop the above plan. Scientists at the Peter Doherty Institute say they are working on a “preventive” vaccine with mRNA technology that can be modified to fight variations. Mr. Merlino said that this plan is an important event, not only for Victoria but for the whole of Australia. Besides, he affirmed that the support budget will be increased when the project is developed in the future. Australia is currently only capable vaccine production of AstraZeneca with the initial plan that the CSL facility in the city of Melbourne will produce more than 50 million doses. Vaccination work COVID-19 Australia is facing many challenges due to the lack of vaccine supplies, as well as the safety of this vaccine related to the side effects of thrombosis.

Covid-19 vaccination for medical staff – Photo: Minh Anh The World Health Organization (WHO) has requested vigilance, monitoring, early detection and timely management of rare human events after Covid-19 vaccination with suspected immune thrombocytopenia. , scattered blood clots in the lumen, cerebral venous thrombosis. The rate of thrombosis after AstraZeneca vaccination is 4.6 / 1 million doses of the first injection, Pfizer-BioNTech Covid-19 vaccine is 0.2 / 1 million doses of the first injection. Thrombosis after AstraZeneca vaccination is mainly seen in women, in Germany there are 29 out of 31 women with thrombosis are women. The rate of blood clotting after AstraZeneca vaccination in young people is higher than in the elderly, especially in the age group 20-29. After vaccination AstraZeneca, the phenomenon of blood clotting seems less likely to occur in people over 60 years old, only about 0.2 / 1 million doses of the first injection. Complications of coagulation after AstraZeneca vaccination depend on genetic factors, underlying disease, lifestyle, medications, factor V Leiden (risk of blood clots). According to the clinical symptom guidelines, the above events are rare and usually appear 4 to 28 days after Covid-19 vaccination with persistent, severe headache; localized neurological symptoms; convulsions, blurred vision, or double vision; difficulty breathing or chest pain; stomachache; pain, swelling of the lower extremities. In particular, patients rarely present with bleeding, skin hemorrhage, or internal bleeding. The Ministry of Health believes that lower level medical facilities can completely handle the clotting phenomenon According to the Ministry of Health, at commune, ward, district or equivalent health centers of grade IV, people should be monitored after vaccination. If at least 1 of the above clinical symptoms appears, it is necessary to transfer the person after Covid-19 vaccination to a higher level or seek emergency treatment if any. In the case of the district hospital, district or equivalent grade III, after injection appears one of the above symptoms need to carry out the following tests: Count the platelet count; basic coagulation tests; quantitative D-dinmer assay; Ultrasound, X-ray exploration … In case of after injection, symptoms need to be transferred to higher level for treatment. At the provincial, city or equivalent level II health facilities, basic tests are needed to count platelet count, and basic coagulation test; quantitative D-dimer assay; imaging tests to assess thrombosis and bleeding; perform other exploration if available. In cases beyond the capacity of diagnosis and treatment, it is necessary to consult a higher level specialist. At the central grassroots level or equivalent grade I, the special class will take in people after vaccination with severe complications transferred by the levels, and carry out all necessary investigations for diagnosis and treatment according to the diagnosis and treatment guidelines of the Ministry of Health; Consult experts as needed. According to the Ministry of Health, by the morning of April 23, an additional 20,203 people were vaccinated against Covid-19 of AstraZeneca. Thus, from March 8 to now, a total of 128,610 people have been vaccinated against Covid-19 of AstraZeneca phase 1 and phase 2 in 28 provinces and cities and have not recorded any cases of blood clots later. injection.

Patient COVID-19 is being treated at a hospital in Bry-Sur-Marne, France, on April 15, 2021. Photo: AFP / VNA Prime Minister Castex confirmed there is evidence that contagion in the past 10 days has tended to decrease. Castex also announced that measures to restrict people from leaving the area within a 10-kilometer radius around the house will be removed from May 3. France is implementing a third blockade to prevent the spread of the SARS-CoV-2 virus, but this prevention measure is considered to be more relaxed than the previous two times. During the 3rd blockade, outdoor activities are still encouraged to improve the mental health of residents. Most of the non-essential stores, cafes, restaurants, and cultural venues are closed. In a new statement, Mr. Castex said that shops, certain cultural and sporting activities and cafes could be reopened from mid-May, depending on the disease situation in Vietnam. at that moment. The French Prime Minister also emphasized that the government will allow regional openings, starting with regions with low COVID-19 prevalence. National curfew from 7:00 p.m. daily remains in place until further notice. Mr. Castex noted this measure will be reevaluated in mid-May but the government has not put in place a firm schedule for easing. To date, France has recorded a total of more than 5.4 million cases of COVID-19, of which 102,164 died. Over the past few days, the number of COVID-19 cases requiring special treatment has been contained below 6,000. After a slow start, the COVID-19 vaccination campaign in France is accelerating, with more than 13 million people getting at least the first shot. From April 24, French people aged 55 and over will be vaccinated with the COVID-19 vaccine from the American pharmaceutical company Johnson & Johnson. This is the fourth COVID-19 vaccine to be licensed in France, after the products of Pfizer / BioNTech, Moderna and AstraZeneca. Meanwhile, to prevent the emergence of new variants of the SARS-CoV-2 virus, the French Ministry of the Interior decided that all passengers from Argentina, Brazil, Chile, India and South Africa would have to undergo quarantine. At the accommodation for 10 days, under the supervision of French police. Currently, health officials in all countries are encouraging the implementation of measures to be alert for the types of viruses with faster spread rates. Also on April 22, Belgian health officials announced the presence of the virus variant in India in this country. Specifically, the new variant was discovered in 20 nursing students from Paris (France) to Belgium in mid-April. The group with a total of 43 students was quarantined upon entry. Experts say the group was infected from a super infectious patient, possibly a member of the group, or from another passenger also on the trip from France to Belgium. A variant of the virus detected in India called B.1.617 has also appeared in several other countries such as the US, Australia, Israel and Singapore. Concerned about this variant, some countries, including the UK, applied a restriction on travel with India.

The overseas new crown vaccine “thrombus gate” continued to ferment. Following AstraZeneca, Johnson & Johnson’s vaccine was also urgently stopped.

On April 13, the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) issued a joint statement stating that in view of the fact that the U.S. has reported 6 cases of “rare and severe” thrombosis after being vaccinated by Johnson & Johnson, It is recommended to suspend vaccination of Johnson & Johnson’s new crown vaccine.

In this regard, vaccine expert Tao Lina (Vaccines and Science) told the reporter of China Times that even if it is finally confirmed that the vaccines of AstraZeneca and Johnson & Johnson have caused rare blood clots, it is necessary to weigh the pros and cons before making a decision.

As the vaccines of AstraZeneca and Johnson & Johnson are both adenovirus vector vaccines, CanSino shares continue to fall sharply. From April 14th to 15th at noon, Cansino A shares reported 349.16 yuan per share, a cumulative decline of about 8% during this period; Hong Kong stocks reported 270.8 Hong Kong dollars per share, a cumulative decline of about 14% during the period.

Johnson & Johnson Vaccines Was Urgently Stopped by the U.S.

According to the official website of the FDA, Johnson & Johnson’s vaccine was approved for emergency use on February 27 for use by people over 18 years of age. It was developed by Johnson & Johnson’s Janssen Pharmaceuticals. This vaccine is an adenovirus vector vaccine. It only requires one dose. The most common side effects are pain at the injection site, headache, fatigue, muscle aches and nausea. Most of these side effects occur within 1-2 days after vaccination, and are mild to moderate and last for 1-2 days.

The above 6 cases of adverse reactions occurred during the vaccination process of more than 6.8 million doses of Johnson & Johnson vaccine, all women aged 18-48, who developed cerebral venous sinus thrombosis and thrombocytopenia at the same time 6 to 13 days after vaccination. This side effect is “extremely rare” and the treatment is different from common blood clots.

On April 14, the CDC’s Immunization Practice Advisory Committee met to discuss these cases, and the FDA has also begun investigating these cases. At present, it has not been confirmed that there is a clear causal relationship between rare thrombotic events and Johnson & Johnson’s new crown vaccine. The two agencies recommended that states suspend continued vaccination against Johnson & Johnson until the complete investigation process is over.

In response, Johnson & Johnson issued a statement on the 13th, saying: “We have been reviewing these cases with European drug regulatory agencies. We have decided to proactively postpone the promotion of the vaccine in Europe, and suspend all clinical trials of the new crown vaccine, and update the research. The guidance of the participants and the participants.”

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the suspension of the Johnson & Johnson vaccine is out of cautious consideration, allowing relevant institutions to further understand the status of patients with adverse reactions and the mechanism of side effects. The probability of such side effects is extremely low, so those who have been vaccinated by Johnson & Johnson need not be anxious.

The health department recommends that people who experience severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after receiving the Johnson & Johnson new crown vaccine should contact their healthcare provider.

At present, the suspension of Johnson & Johnson vaccination will not have a major impact on the progress of the new crown vaccination in the United States. Jeff Zienz, an expert on the US White House’s New Crown Epidemic Response Team, said that Johnson & Johnson vaccines account for less than 5% of the current US vaccination records. The US government is working with states and partners to help the Johnson & Johnson vaccines that have been booked. The patient should be rescheduled to receive Pfizer or Modena vaccine as soon as possible.

In fact, four days before the United States stopped Johnson & Johnson’s vaccination, the European Union has begun to review the safety of the vaccine. The vaccine was approved for conditional marketing in the EU in March, but has not yet been delivered. According to the plan, Johnson & Johnson will provide at least 200 million doses of the new crown vaccine to the EU within this year.

Following AstraZeneca’s footsteps?

It seems that Johnson & Johnson has followed in the footsteps of another multinational giant, AstraZeneca.

In March, due to the symptoms of bleeding, thrombosis and reduced platelet counts among medical staff in Denmark, Norway and other places after vaccination, nearly 20 countries including Germany, France, Denmark, Norway, Iceland, Italy, Thailand, Austria, etc. once called for a stop. Sleek vaccination.

On April 7, expert teams from the European Medicines Agency (EMA) and the World Health Organization (WTO) successively issued statements stating that the vaccine developed by AstraZeneca and the University of Oxford may be related to rare blood clots. The EMA Safety Committee (PRAC) believes that rare thrombosis with thrombocytopenia should be classified as a very rare side effect of the AstraZeneca vaccine. However, the overall benefits of the vaccine in preventing new coronary pneumonia outweigh the risk of side effects.

PRAC conducted an in-depth review of the 62 cases of cerebral venous sinus thrombosis and 24 cases of splenic vein thrombosis reported in the EU drug safety database as of March 22, 2021. Among them, 18 cases were fatal. These cases were mainly from the spontaneous reporting system of the EU and the United Kingdom. Approximately 25 million people have received the vaccine.

PRAC pointed out that thrombosis occurs in cerebral veins (cerebral venous sinus thrombosis) and abdominal veins (splenic vein thrombosis) and arteries, accompanied by low platelet levels and sometimes bleeding. So far, most of the reported cases have occurred in women under 60 years of age within 2 weeks of vaccination.

AstraZeneca said that it will update the vaccine product instructions and add information about the vaccine and “very rare” thrombosis on the new label. Together with the WTO and EMA, we are conducting unified observations on patients with symptoms after vaccination and conducting further research.

At present, many countries have announced adjustments to the AstraZeneca vaccination groups, including the United Kingdom, the Philippines, Australia, South Korea, Belgium, etc., but there are differences in age. The United Kingdom advises against vaccinating AstraZeneca for people under 30 years of age, Belgium suspends vaccinations for people 55 years of age and under, Australia suspends vaccinations for people under 50 years of age, and Spain, South Korea and the Philippines only for people over 60 years of age Get the vaccine.

Recently, the “New England Journal of Medicine” published two important studies at the same time, analyzing the symptoms of thrombosis and thrombocytopenia in patients after vaccination with AstraZeneca.

In the first study, the Norwegian research team reported that 5 cases of rare venous thrombosis and thrombocytopenia were found in more than 130,000 vaccinators. High levels of antibodies against PF4-polyanion complex were detected in the blood of all patients. This antibody can activate platelets, leading to abnormal formation of thrombus and a decrease in the number of free platelets.

In the second study, the German research team analyzed the clinical and blood test data of 11 patients who experienced thrombosis or thrombocytopenia after being vaccinated with AstraZeneca in Germany and Austria. Testing of patients’ blood samples also found high levels of antibody responses to PF4-heparin complex or PF4. Historical studies have shown that other factors besides heparin may also trigger symptoms very similar to heparin-induced thrombocytopenia.

China’s Cansino vaccine implicated

It is worth noting that the vaccines of Johnson & Johnson and AstraZeneca both follow the path of adenovirus vector technology. Now that one after another is involved in the “thrombus gate”, are other adenovirus vector vaccines still safe?

At present, in addition to Johnson & Johnson and AstraZeneca, the satellite 5 (Sputnik-V) developed by Russia, and the new crown vaccine developed by China’s Cansino Biotechnology Co., Ltd. also belong to the adenovirus vector technology path. However, according to public information, the adenovirus vectors used in these four vaccines are different. The AstraZeneca vaccine uses the chimpanzee adenovirus vector, the Johnson & Johnson vaccine is based on the Ad26 adenovirus vector, and the Cansino vaccine uses the Ad5 adenovirus as the carrier. The first dose of the Russian satellite 5 vaccine uses Ad26 as the carrier, and the second dose uses Ad5 as the carrier. Carrier.

Affected by this news, Cansino’s stock price plummeted, A shares fell by 13%, and H shares fell by 18%. CanSino Bio had to issue an emergency statement stating that the Ad5 vector used by the company’s new crown vaccine is a common adenovirus that infects humans, which is different from the adenovirus vector used by AstraZeneca and Johnson & Johnson vaccines. As of the 14th, about one million people vaccinated with Cansino vaccine have not received reports of serious adverse events related to thrombosis. After the company’s statement was issued, the decline in Cansino’s share price narrowed. As of the close, Cansino A shares closed at 356.20 yuan per share, the decline narrowed to 6%; the decline of Hong Kong stocks also narrowed to 8%.

CITIC Securities believes that this phenomenon has not been found among the millions of vaccinators of Cansino vaccine; this has not been found in the previous use of Ad5 in other vaccines and drugs; after all, Ad5 is a viral vector with a high infection rate in humans. It is different from AstraZeneca, Johnson & Johnson and Carrier, and the probability of thrombosis is very different.

So, is Ad5 adenovirus vector safer? Taolina said that there are some studies on the thrombocytopenia caused by adenoviral vectors, but these studies are based on the results of high-dose systemic therapeutic applications.

In September 2011, Yu Xiunan and other researchers from the First Affiliated Hospital of Harbin Medical University published an article “Research Progress in Adenovirus Type 5 and Thrombocytopenia” in the Journal of Modern Laboratory Medicine, which mentioned that thrombocytopenia Symptoms are a major side effect of high-dose systemic application of adenovirus as a vector for gene therapy of carriers. Adenovirus can bind to CAR receptors on platelets, and can also bind to integrin receptors on platelets. “Recent studies have found that adenovirus may cause activated platelets. Adenovirus-induced thrombocytopenia is considered to be dose-dependent, saturated and reversible, which is consistent with the ligand-receptor mechanism. There are multiple views on the mechanism.”

Regarding the Johnson & Johnson vaccine, “I’m still suspending the use and continuing to evaluate it, but compared to no vaccination, I am expressly willing to accept the adenovirus vector vaccine.” Taolina said.

AstraZeneca’s COVID-19 Vaccine. (Photo: VNA broadcast) Regarding the issue of vaccine supplies of the European Union (EU), on April 18, the European Commissioner for the internal market Thierry Breton left open the possibility that the EU could decide not to continue ordering. vaccine of AstraZeneca due to a later than agreed upon delivery. The EU initially ordered 120 doses of AstraZeneca vaccine for 27 member countries in the first quarter of 2021 and 180 million doses in the second quarter of 2021. However, so far AstraZeneca has only delivered 30 million doses and is expected to have only 70 million more doses in the next quarter. Mr. Breton affirmed that there is currently no certainty and the EU is still negotiating with AstraZeneca. However, he stressed that no matter what the decision is not due to medical or epidemiological reasons, and affirms that the AstraZeneca vaccine brings more benefits than risks. U] Previously, on April 16, French Industry Minister Agnes Pannier-Runacher also mentioned the possibility that the EU will not renew the contract with AstraZeneca and both. Johnson & Johnson in the year 2022. Some EU countries have stopped using the AstraZeneca vaccine due to concerns about the risk of side effects occurring thrombosis. However, most countries have resumed their AstraZeneca vaccination program after the European Drug Administration (EMA) confirmed the safety and effectiveness of the vaccine.

CDC Can Tho receives vaccines. Photo: VNA broadcast Accordingly, the vaccine has been safely transported by the Pasteur Institute of Ho Chi Minh City to the Center for Disease Control in Can Tho City. Immediately after receipt, all of these vaccines were stored in cold storage by the unit and stored in accordance with regulations, as well as recommendations of the manufacturer. The system of cold chain for storing vaccines of the Center for Disease Control in Can Tho city today, including: refrigerators, specialized cold boxes, vaccine thermos bottles, automatic temperature monitoring devices … meet the standards. about vaccine preservation. Recently, the unit also received 4 additional dedicated vaccine storage cabinets TCW 4000 AC, each with a storage capacity of about 60,000 doses of AstraZeneca vaccine. The room COVID-19 AstraZeneca vaccine was researched and developed by Oxford University and the World Health Organization through approval for emergency vaccines on February 15. Updated to March 8, the vaccine has been used in 98 countries around the world. In Vietnam, the COVID-19 AstraZeneca vaccine has been conditionally approved by the Ministry of Health as a vaccine for urgent needs in the prevention and control of COVID-19 in Decision No. 983 / QD-BYT dated 1/2/2021. CDC Can Tho receives vaccines. Photo: VNA broadcast AstraZeneca vaccine is bottled in 10 doses / vial, 100 vials / box, stored at 2-8 degrees Celsius and not frozen. This vaccine is indicated for vaccination against people 18 years of age and older; Intramuscular injection, dose of 0.5ml. 2 doses of 2 doses are recommended, each 12 weeks apart. In 2 days, April 19-20, at the Center for Disease Control in Can Tho City (CDC Can Tho), the competent forces will pre-inject some people with the participation in monitoring and sharing experiences. of the Pasteur Institute of Ho Chi Minh City. On the basis of learning from experience, the forces will deploy simultaneous injections at fixed injection points in the city on April 22-24, including: 7 hospitals, City Center for Disease Control Can Tho and 9 district health centers. Priority subjects who have not yet been vaccinated will receive additional injections from April 27-29. The Center for Disease Control in Can Tho city notes that vaccinated people strictly follow the instructions of the Ministry of Health to ensure safety in vaccination against COVID-19. CDC Can Tho receives vaccines. Photo: VNA broadcast * Tuyen Quang province has received 4,500 doses of AstraZeneca vaccine for COVID-19 room from the National Institute of Hygiene and Epidemiology. These vaccines were transferred to the Center for Disease Control of Tuyen Quang province and stored in a cold chain system, at a temperature of 2-8 degrees Celsius. It is expected that all 4,500 doses of vaccine will be given priority to vaccinate phase 1 for free for those who are frontline anti-epidemic forces: People working in health facilities; people involved in epidemic prevention; army and police force. Mr. La Dang Re, Deputy Director of the Department of Health of Tuyen Quang province, said that the Department organized a training course for medical units in the province on COVID-19 vaccination; plan to organize 2 injections. In particular, the first phase injected about 1,000 doses at 3 points, which are Tuyen Quang Provincial General Hospital, Provincial Public Security Hospital and Phuong Bac Hospital. In order to prepare well for the vaccination work in the area, the provincial health sector has prepared manpower and equipment, ensuring that all injection sites are strictly arranged according to one-way regulations. Those who are vaccinated will be screened before first vaccination, monitored 30 minutes after injection, followed by 7 days to ensure safety. The Department of Health of Tuyen Quang province has directed the units to urgently make a list of priority subjects; organizing training courses, guiding the reception, use, preservation of COVID-19 vaccines and monitoring of post-injection adverse events; prepare sufficient human resources and equipment to meet the situations before deploying vaccination. From April 19, the functional forces will deploy vaccination in Tuyen Quang city; early May 2021 will be vaccinated in the districts of the province.

COVID-19 vaccine from Johnson & Johnson. Photo: AFP / VNA On April 13, US federal health authorities recommended to suspend the use of Johnson & Johnson’s COVID-19 vaccine for “cautious” reasons, awaiting the results of investigating the possible link between the vaccination. this with thrombotic side effect. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are reviewing six cases of thrombosis following the vaccination. Meanwhile, according to Reuters, on April 15, US infectious disease expert Anthony Fauci hopes that US regulators will soon make a quick decision on resuming Johnson & Johnson’s vaccination, bringing the vaccine back. immunization program. The day before, the US CDC advisory committee postponed at least a week to vote on whether to resume use of the Johnson & Johnson vaccine to wait for more data on thrombotic risks. Mr. Fauci feared that the prolonged delay of the vaccine could affect people’s hesitancy. “I think we need to continue to emphasize that this is a very effective and usable vaccine that is very, very valuable in a global context,” he said. Following the US, some countries have made similar moves with the Johnson & Johnson vaccine
On April 13, the South African Ministry of Health announced it had suspended the use of the Johnson & Johnson vaccine in the country’s vaccination program, although South Africa has not received a report related to coagulation after 290,000 people in the country. has received the COVID-19 vaccine from the brands. Two weeks ago, South Africa licensed the use of vacicne Johnson & Johnson and so far only vaccinated this vaccine to health workers in the study framework. Before the above developments, Dutch Health Minister Hugo de Jonge said that the country has not decided whether to launch the Johnson & Johnson vaccine injection this week or not. He stated that the Netherlands will wait for information from the European Pharmaceutical Authority (EMA) before making a decision. In contrast, some countries continue to use the Johnson & Johnson vaccine. Belgium has said it will not stop the vaccination at this stage. Poland started to vaccinate Johnson & Johnson when the government confirmed that the benefits of the vaccine outweigh the risks. Meanwhile, Spanish officials have not received the notice of stopping the Johnson & Johnson vaccination. For its part, the World Health Organization (WHO) says it is monitoring global data of various reports to see if similar cases occur elsewhere, and it will take time. Time to evaluate vaccine data from Johnson & Johnson. Denmark completely discontinues the AstraZaneca vaccine; Thailand is still considered the mainstay Prime Minister of Thailand Prayut Chan-O-Cha (middle) was vaccinated against COVID-19 by AstraZeneca company in Bangkok, on March 16, 2021. Photo: AFP / VNA Before the Johnson & Johnson vaccine, the AstraZeneca vaccine was also in the same situation. The AstraZeneca vaccine is suspected of causing thrombosis, causing a series of European countries to suspend use, despite WHO recommendations. Recently, on April 14, Denmark became the first European country to permanently stop using the AstraZeneca vaccine due to concerns about rare blood clotting side effects. Denmark thinks that AstraZeneca’s vaccine may not be needed because it has managed the COVID-19 pandemic and may just depend on the vaccines from Pfizer and Moderna. Before that, from March 11, Denmark, along with Iceland and Norway, have suspended the use of this vaccine. Followed by a number of other European countries, including France, Germany and Italy. Federal Health Ministers and states in Germany unanimously recommend a second shot after getting the first shot with the AstraZeneca vaccine, under which one shot of the preparation is given to those under 60 years of age. This could be a second shot with another vaccine. In Bulgaria, Health Minister Kostadin Angelov also announced that the launch of AstraZeneca’s vaccine in the country could be stopped because people are not interested. The European Drug Administration – the European Union’s (EU) drug regulator – then recommended that countries continue to use vaccines as the benefits of vaccines far outweigh any potential risks. hidden from humans. Last week, the European pharmaceutical regulator listed clotting as an extremely rare side effect of the AstraZeneca vaccine. Some countries have started to re-use the vaccine after the suspension, but limited in the number of people vaccinated. As is the case in the UK, the country says it will offer another vaccine for people under the age of 30. While some countries are vaccinated with AstraZeneca, Thailand Health Minister Anutin Charnvirakul announced that the AstraZeneca vaccine will be the mainstay of the Southeast Asian country’s COVID-19 vaccination program. Mr. Anutin confirmed that Thailand has the expertise to closely monitor vaccine information and the decision is based on science. Thailand’s vaccination campaign mainly relies on domestically produced AstraZeneca vaccine and 2 million doses of Chinese vaccine to vaccinate about 35 million people, equivalent to 50% of the population – Thailand’s goal. must be reached by the end of 2021. Along with Thailand, Korea has decided to continue to vaccinate AstraZeneca for those who qualify. People younger than 30 years of age have not yet received the vaccine because the risk of blood clots outweighs the benefit of the vaccination. Continued reassurance and investigation of coagulation phenomenon after vaccination Health care workers give COVID-19 vaccine to people in Llanelli, South Wales (UK), April 9, 2021. Photo: AFP / VNA While countries are moving differently with the Johnson & Johnson and AstraZeneca vaccines, WHO continues to assert the benefits of COVID-19 vaccination. On April 15, WHO Director in Europe Hans Kluge reaffirmed that the benefits of the AstraZeneca vaccine outweigh the risks. “Make it clear that there is no doubt that the AstraZeneca vaccine is effective in reducing hospital admissions for COVID-19 and preventing severe illness that leads to death. The WHO has recommended this vaccine as soon as possible,” he said. as possible for adults to increase resistance to the SARS-CoV-2 virus “. WHO officials also pointed out that out of the 200 million people who got the AstraZeneca vaccine, there are only a few rare cases of a blood clotting disorder. He emphasized that the risk of blood clots in patients with COVID-19 is much higher than in those receiving the AstraZeneca vaccine. A study by scientists at the University of Oxford UK showed that COVID-19 patients have a higher risk of developing blood clots in the brain than those vaccinated against the disease. Data from over 500,000 patients with COVID-19 show that blood clotting occurs at an incidence of 39 out of 1,000,000 patients. Of the more than 480,000 people who received the COVID-19 vaccine made by BioNTech / Pfizer or Moderna, the incidence of coagulation was 4 / 1,000,000, while the rate was slightly higher for those receiving the vaccine. AstraZeneca – about 5 / 1,000,000 after the first injection. After the coagulation incident with the Johnson & Johnson and AstraZeneca vaccines, the researchers found that this rare side effect only occurs with vaccines using adeno virus vector technology (the virus that causes the common cold). There has been no record of coagulation in people who received the vaccine using other technologies from Pfizer and Moderna. However, the link between the technology using adeno virus vectors and coagulation is only a simple guess, there is no evidence. Russian vaccine has not caused any blood clotting cases and is increasingly “expensive”. Vaccine Sputnik V in Moscow, Russia. Photo: AFP / VNA When Western countries investigated blood clotting side effects, the Gamaleya Research Institute – which develops the Russian vaccine Sputnik V – said the vaccine has not caused any adverse reactions related to blood clotting. According to the Gamaleya Institute, there is no reason to equate the safety of the Johnson & Johnson, AstraZeneca vaccines with Sputnik V. All three of these vaccines are vector-based, using the adeno virus to deliver the protein of SARS-CoV- 2 into human cells, helping to stimulate the immune system’s response. However, all three manufacturers use different structures and technologies in vaccine formulation. Iran is the latest country to order Russian vaccines. Iranian Ambassador to Russia Kazem Jalali confirmed that the contract to buy 60 million doses of Sputnik V has been signed and completed, enough to give 2 doses to 30 million people. Ambassador Kazem Jalali also announced that Iran will receive the vaccine by the end of 2021. Russia is also transferring technology to produce this vaccine to a number of countries. Most recently, the Korean company ISU Abxis on April 15 announced an agreement with the Russian Direct Investment Fund (RDIF) on the technology transfer and production of Russia’s Sputnik V vaccine for Korean companies. . It is expected that the production of vaccine trials will soon be deployed at a facility in Yongin, south of Seoul. The Russian Sputnik V vaccine is the second most popular vaccine in the world approved for use by national pharmaceutical regulators.

By A. Meyer-Fünffinger, J. Schuster, A. Wetter and M. Zierer, BR Four million doses of the Covid-19 vaccine from AstraZeneca: The regional government of Apulia apparently wanted to buy this amount – enough to be able to administer one dose of vaccine to the entire population of the southern Italian region. This is what it says in a letter that the head of the Apulian crisis team sent to AstraZeneca at the end of January. It suits that Bavarian Broadcasting and its international research partners IrpiMedia in Italy and Follow the Money in the Netherlands in front. Apparently, a direct deal between a regional government and AstraZeneca was planned, threaded through private brokers and handled through a complex network of companies. The deal does not go through, and in the meantime the prosecutor in Perugia has started investigations into suspected fraud.

Spahn speaks of a gold rush mood

After joint research by the BR With the international research partners, dealers across Europe offer vaccines to authorities and governments – bypassing central procurement via the EU Commission: in the Netherlands, for example, in Estonia or in Denmark. Vaccines are offered by AstraZeneca and BioNTech, including the Russian vaccine Sputnik V, which has not yet been approved in the EU.

Health Minister Spahn sees a “gold rush mood” among the providers. Image: dpa The German Ministry of Health is also repeatedly offered vaccines from different manufacturers, Federal Health Minister Jens Spahn confirmed in Berlin last week: “It’s a bit like in this pandemic with different products over and over again: it creates a gold rush atmosphere.” The pharmaceutical company AstraZeneca writes down BR-Inquiry that there is currently no supply, sale or distribution of the vaccine by the private sector. If someone offers private vaccines, it is “likely to be counterfeit,” said a spokeswoman.

Braid around a Stuttgart businessman

Behind the planned deal in Apulia is a complicated network of companies involved: A central figure is apparently a doctor from Stuttgart. He was the managing director of a Swiss company owned by his daughter. He does not make deals himself, but sees himself as an intermediary between pharmaceutical companies and governments, he tells reporters from BR Research / BR Data on the phone. A detailed written request remains unanswered. From an invoice that the BR is available, it appears that the cans should apparently be obtained through a dealer in the United States. Alleged origin of the vaccine: the United Kingdom. Also involved: two Hungarian “partner companies” of the Stuttgart businessman – one of them a furniture manufacturer. When asked, they do not know anything about vaccines for the Apulia region.

European anti-fraud agency investigated

The FDP European parliamentarian Andreas Glück speaks of “black sheep” on the vaccine market: “We definitely cannot accept that. The best way to protect ourselves from this is to work together at European level. Presumably everything did not go smoothly with the vaccine procurement at European level, we have to improve. ” The subject is known to the EU Commission. On request, a spokesman referred to the investigation by the European anti-fraud authority OLAF:

These offers come in many different forms. For example, the scammers offer to sell large quantities of vaccines, deliver a sample to collect the first advance payment, and then disappear with the money. They can supply batches of counterfeit vaccines. Or they pose as a representative of a legitimate company and claim they have or have access to vaccines. All of these claims have one thing in common: they are false. The EU Commission therefore calls on local authorities to be very careful if they receive offers of this kind.

Doubtful offers also in Germany

Some federal states have also received offers for vaccines, for example Schleswig-Holstein. The local Ministry of Health writes on request that at the end of March an individual contacted the country by email and pretended to be able to establish contact with a wholesaler. It was about five million doses of the BioNTech vaccine. No indication of the price. The Mainz vaccine manufacturer BioNTech agrees BR with that his vaccine is sold exclusively to governments and government-like organizations such as the European Commission. “BioNTech has no other sales channels,” writes the company. The Baden-Württemberg Ministry of Health followed up BR-Information an offer on the Russian vaccine Sputnik V. “Please send us a formal offer stating an initial purchase quantity of 1 million and the price offer,” wrote a company from Singen, which specializes in the import of medical cannabis from the Netherlands.

Investigations in Baden-Württemberg

In Stuttgart, the public prosecutor’s office is now investigating “after a private person allegedly appeared to a ministry as (alleged) mediator of vaccines,” as it was called upon request. The examination of the facts continues. Such offers were also available in Hesse, North Rhine-Westphalia and Bremen. All federal states have said they have rejected it. The Association of Research-Based Pharmaceutical Companies emphasizes BR-Inquiry that caution should always be exercised with corona vaccines “when ‘intermediaries’ contact government agencies”. The Federal Association of Pharmaceutical Wholesalers goes one step further and demands that the distribution channel of vaccines for delivery from the manufacturer via pharmaceutical wholesalers and pharmacies to medical practices must be laid down. All alternative distribution channels and structures would run the risk of undermining the legal supply chain, jeopardizing the safety of the vaccines and thus the safety of the population to be vaccinated.

A woman wearing a mask passed by the National Health Service (NHS) Covid-19 vaccination site in London (UK) on March 31. Photo: Tan Hoa commune

According to CNN, Dr. Carissa Etienne, Regional Director of the Americas of the World Health Organization (WHO), countries should continue to use vaccines by AstraZeneca firm (UK – Sweden) in collaboration with Oxford University (UK) research, as well as WHO-approved vaccines. According to Dr. C.Etienne, nearly 200 million people worldwide have been vaccinated against the Covid-19 vaccine from AstraZeneca / Oxford and reports of side effects are rare …

Europe

On April 14, President of the European Commission (EC) Ursula von der Leyen announced that the European Union (EU) will promote the handover of Pfizer / BioNTech vaccines to compensate for the Johnson & Johnson vaccines. postponed handover. It is expected that the total number of Pfizer / BioNTech vaccines delivered to Europe in the second quarter will be 250 million, representing more than 50% of the total injected doses this quarter. This is a move to secure vaccine demand in the long term to prevent the development of new strains of the SARS-CoV-2 virus.

Reuters quoted some diplomatic sources as saying that EU countries have agreed to implement the vaccine passport initiative towards reopening the tourism industry in the summer. Details of this initiative will be discussed with the European Parliament (EP) in May.

According to the previously announced vaccine passport initiative, those with a certificate of vaccination have recovered from Covid-19 or tested negative for SARS-CoV-2. will be allowed to travel easily between EU countries.

The EU countries also agreed against discrimination against those who cannot or do not wish to be vaccinated against Covid-19.

Carolina Health Minister Darias said Spain has received 146,000 doses of Johnson & Johnson’s Covid-19 vaccine and will use them in the injections as soon as the European Drug Administration (EMA). approved for the safety of this vaccine.

On April 14, Spanish Prime Minister Pedro Sanchez said he would extend a three-month extension of measures to protect groups believed to be vulnerable to the economic impact of the Covid-19 pandemic. , namely those who have to rent a house. These individuals will not have a rent increase, a tenancy agreement will not be terminated and may apply for a temporary or partial rent delay or reduction.

Ukraine’s capital Kiev will extend the blockade until April 30 after the daily number of new infections and deaths from Covid-19 continues to rise, despite the strict restrictions imposed from May. 3. Kyiv Mayor Vitali Klitschko expressed concern that, if this decision is not made, the health system will be overloaded and thereby increasing the number of deaths caused by Covid-19. Kiev currently records about 1,500 new infections and more than 40 deaths a day from the epidemic.

The media of the Czech Republic reported that Germany would end the regular border controls with this country, which were applied from February 14 due to the complicated situation of the Covid-19 epidemic.

Asia

On April 14, the Indian government said that the country would cancel the 10th grade exam and postpone the 12th grade exam due to the skyrocketing number of Covid-19 cases. Specifically, the Indian Ministry of Education announced that the 10th grade exam scheduled to take place from 4-5 to June 14 will be canceled, and the results will be ranked according to the criteria set by this ministry. Grade 12 exams scheduled to take place during the above time will be postponed and held later.

India is witnessing a sharp increase in the number of new Covid-19 cases. On April 14, the country continued to record with an additional 184,372 cases positive for the SARS-CoV-2 virus, the highest level in 1 day since the outbreak.

On April 14, strict blockade measures took effect in Bangladesh to control a new wave of infections. During the eight days of a blockade, people were only allowed to go out to buy medicine, food or in emergencies.

Americas

According to the scientists, the P1 variant of the SARS-CoV-2 virus was first discovered in Brazil and is the main cause of the country’s new wave of infection, which is mutating that it avoids good antibodies. than. Changes in this strain could cause the virus to increase resistance to the vaccine, affecting the severity of an outbreak in the most populous country in Latin America.

Step 1: Access to https://www.bluezone.gov.vn or directly download at App Store or Play Store.

Step 2: Once downloaded, the app will ask for Bluetooth permission to record contact with other Bluezone installed users. If Bluetooth isn’t open, drag the status notification bar and turn on Bluetooth; Or go to Settings, select Bluetooth and turn it on.

Step 3: After the installation is complete, click Scan Around. If someone near you less than 2m has used Bluezone, the application will automatically identify these users and put them on the contact list.

AstraZeneca’s COVID-19 vaccine. Photo: AFP/TTXVN

According to the Ministry of Health, the man was injected with a vaccine produced at India’s Serum Institute. The patient has returned home and is in the process of recovering.

Earlier, Canada limited AstraZeneca’s vaccine use to people over the age of 55 due to concerns about the rare reaction. The above information is the latest challenge for vaccination in Canada.

In addition, Health Canada confirmed that it is in discussions with Johnson & Johnson about the possibility of a COVID-19 vaccine. The department has asked Johnson /Johnson for information on any cases of post-injection blood clots. The agency is also working with the U.S. Food and Drug Administration (FDA) and other international agencies on the issue.

Although Canada has licensed Johnson&Johnson’s vaccine, the vaccines ordered will not be shipped until the end of April. Canada is expected to get enough vaccines so that by the end of June, each citizen can get one shot. However, the rate of spread of the new variants of the SARS-CoV-2 virus is surpassing the progress of vaccination in the country.

The number of new cases in the last week has increased by 33%, while the number of new daily infections is at more than 8,100, equivalent to the peak of the second wave of outbreaks earlier this year. Canadian Prime Minister Justin Trudeau warned more dangerous new variations were spreading rapidly and threatened progress had been made.

According to statistics worldometers.info, Canada has a total of over 1 million infections and over 23,000 deaths from COVID-19.

* Meanwhile, Australia announced that it will send Trade Minister Dan Tehan to Europe on April 15 amid reports that it has ordered more than 3 million doses of AstraZeneca’s vaccine made in the European Union (EU) but has not received the goods.

Under the plan, Minister Tehan will have dialogues with his German, French and EU colleagues to discuss eu production and export limits on AstraZeneca’s vaccines.

Australia is one of the countries that succeeds in controlling the COVID-19 epidemic. Since the outbreak, the country has recorded nearly 30,000 cases. However, Australia is currently behind in its vaccination campaign. As of April 11, Australia had only vaccinated nearly 1.2 million people, despite a pledge by the end of March to vaccinate 4 million people.

The Australian government believes that the EU’s non-delivery of the vaccines it ordered by AstraZeneca was the cause of the delay in the vaccination program, but state authorities pointed out that the distribution of vaccines to health facilities also contributed to this situation.

Under pressure from public opinion, Australian Prime Minister Scott Morrison said he would convene a cabinet meeting twice a week with state and territory leaders until the issue was resolved and put the vaccination program back on track.

Australia intends to vaccinate the majority of the population with AstraZeneca’s vaccine, which has imports from Europe and domestic production, while waiting for supplies from Pfizer and Novavax. The Australian government recently admitted it may not meet its target for COVID-19 vaccination for all residents next October due to import delays and new concerns about vaccine side effects.

* In Ireland, Health Minister Stephen Donnelly said the country is considering extending the vaccination period between Pfizer/BioNTech’s two doses to more than 4 weeks to maintain the vaccination progress, amid concerns that other vaccines such as AstraZeneca and Johnson /Johnson are being restricted from use due to safety risks.

In Russia, President Vladimir Putin confirmed he had given two shots against COVID-19. Speaking on television, Mr Putin expressed hope people would do the same to take care of themselves and their loved ones.

On March 23, President Putin received his first shot of the COVID-19 vaccine.

The Kremlin did not specify the type of vaccine the Russian President was vaccinated against, but insisted it was among three Russian-developed vaccines including Sputnik V, EpiVacCorona and CoviVac. In the interview, Mr Putin said he had suffered minor side effects such as muscle pain after his first injection but did not have a fever.